Overview
- AstraZeneca reported stronger third-quarter results with profit after tax of $3.12 billion and group revenue of $16.2 billion, driven largely by cancer drugs.
- The group has opened a Reshaping for Sustainable Growth programme that will cost $2.0 billion upfront and aims to deliver $1.5 billion in annual savings to be reinvested in its drug pipeline.
- Oncology accounted for 48% of Q3 revenue and management said the firm has multiple potential blockbuster assets in late-stage development that the savings will help advance.
- The company has continued external investments to bolster R&D, including a reported $2 billion stake in Summit Therapeutics and a partnership with AI drug developer Insitro worth up to $1.5 billion.
- AstraZeneca reiterated its $80 billion by-2030 ambition, plans to lean more on US sales and a $15 billion China investment, and faces medium-term pressure from patent losses and prior trial setbacks that the reinvestment aims to offset.